HUE046702T2 - Eljárások üvegcsontbetegség kezelésére - Google Patents
Eljárások üvegcsontbetegség kezeléséreInfo
- Publication number
- HUE046702T2 HUE046702T2 HUE17206987A HUE17206987A HUE046702T2 HU E046702 T2 HUE046702 T2 HU E046702T2 HU E17206987 A HUE17206987 A HU E17206987A HU E17206987 A HUE17206987 A HU E17206987A HU E046702 T2 HUE046702 T2 HU E046702T2
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- osteogenesis imperfecta
- treating osteogenesis
- treating
- imperfecta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361803647P | 2013-03-20 | 2013-03-20 | |
US201361875399P | 2013-09-09 | 2013-09-09 | |
US201361883151P | 2013-09-26 | 2013-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE046702T2 true HUE046702T2 (hu) | 2020-03-30 |
Family
ID=50483613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17206987A HUE046702T2 (hu) | 2013-03-20 | 2014-03-20 | Eljárások üvegcsontbetegség kezelésére |
Country Status (27)
Country | Link |
---|---|
US (4) | US9598486B2 (hu) |
EP (3) | EP2976359B2 (hu) |
JP (3) | JP6483086B2 (hu) |
KR (1) | KR102257138B1 (hu) |
CN (2) | CN111000997A (hu) |
AU (1) | AU2014235933B2 (hu) |
CA (1) | CA2907422C (hu) |
CL (1) | CL2015002801A1 (hu) |
DK (2) | DK2976359T4 (hu) |
EA (1) | EA032327B1 (hu) |
ES (2) | ES2763869T3 (hu) |
HK (2) | HK1213576A1 (hu) |
HR (2) | HRP20181939T4 (hu) |
HU (1) | HUE046702T2 (hu) |
IL (2) | IL241461B (hu) |
LT (2) | LT3312195T (hu) |
MX (2) | MX369360B (hu) |
MY (1) | MY172324A (hu) |
PH (2) | PH12015501864B1 (hu) |
PL (2) | PL2976359T5 (hu) |
PT (2) | PT2976359T (hu) |
RS (2) | RS59673B1 (hu) |
SG (2) | SG10201701985YA (hu) |
SI (2) | SI3312195T1 (hu) |
TW (1) | TWI629995B (hu) |
UY (1) | UY35493A (hu) |
WO (1) | WO2014153435A1 (hu) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3312195T1 (sl) * | 2013-03-20 | 2020-02-28 | Genzyme Corporation | Postopki zdravljenja osteogeneze imperfecta |
CA3033614A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | Tgf-.beta. antagonist conjugates |
CN106755395B (zh) * | 2016-12-16 | 2020-05-12 | 山东第一医科大学(山东省医学科学院) | Xi型成骨不全致病基因fkbp10的突变位点及其应用 |
AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
WO2018134681A1 (en) * | 2017-01-20 | 2018-07-26 | Sanofi | Anti-tgf-beta antibodies and their use |
TWI787230B (zh) * | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
TWI788321B (zh) * | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
US20190248881A1 (en) * | 2017-12-04 | 2019-08-15 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
AU2019301283A1 (en) | 2018-07-10 | 2021-02-04 | Sanofi | Combination therapies against cancer targeting CD38 and TGF-beta |
CA3196077A1 (en) * | 2020-10-23 | 2022-04-28 | Hq Han | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof |
CN117730095A (zh) * | 2021-05-07 | 2024-03-19 | 贝勒医学院 | 中度至重度成骨不全症的治疗 |
CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
MX2024005344A (es) * | 2021-11-01 | 2024-07-19 | Genzyme Corp | Tratamiento de la osteogenesis imperfecta. |
WO2024149381A1 (en) * | 2023-01-13 | 2024-07-18 | Shanghai Kaijin Biotechnology, Ltd | Multi-specific polypeptide complexes |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6716836A (hu) * | 1967-12-11 | 1969-06-13 | ||
US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO2000028982A2 (en) * | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
JP4813660B2 (ja) * | 1998-11-27 | 2011-11-09 | ダーウィン ディスカバリー リミテッド | 骨鉱化作用を増加するための組成物および方法 |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
CN101163502A (zh) | 2005-02-08 | 2008-04-16 | 根茨美公司 | 针对TGFβ的抗体 |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2007076391A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
KR20180083967A (ko) * | 2007-02-09 | 2018-07-23 | 악셀레론 파마 인코포레이티드 | 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
EP2142924A2 (en) * | 2007-04-26 | 2010-01-13 | President And Fellows Of Harvard College | Assays for the identification of compounds that modulate bone formation and mineralization |
AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
AU2009206082A1 (en) * | 2008-01-15 | 2009-07-23 | Kalobios Pharmaceuticals, Inc. | Methods of treating bone-loss disorders using a GM-CSF antagonist |
ES2702049T3 (es) * | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
SI3312195T1 (sl) * | 2013-03-20 | 2020-02-28 | Genzyme Corporation | Postopki zdravljenja osteogeneze imperfecta |
-
2014
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en active Application Filing
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active IP Right Grant
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en active Pending
-
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864B1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
- 2015-09-18 MX MX2019009122A patent/MX2019009122A/es unknown
-
2016
- 2016-02-11 HK HK16101478.1A patent/HK1213576A1/zh unknown
- 2016-02-11 HK HK18112865.7A patent/HK1253717A1/zh unknown
-
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
-
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261A1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
-
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
-
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US20220195025A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287915A (en) | Methods for treating brittle bones | |
IL240713A0 (en) | Complexes for handling materials | |
PL2983787T3 (pl) | Sposób leczenia zespołu stresu pourazowego | |
GB201307442D0 (en) | Process Apparatus | |
HK1220155A1 (zh) | 治療癌症的方法 | |
GB201318983D0 (en) | Radiotherapy apparatus | |
AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
HK1215164A1 (zh) | 處理方法 | |
HUE042470T2 (hu) | Eljárás széntartalmú anyagok kezelésére gõz termolízissel | |
IL245541A0 (en) | New methods for the treatment of neurodegenerative diseases | |
ZA201604486B (en) | Timber treatment process | |
PL3016682T3 (pl) | Sposoby leczenia nowotworu | |
EP2941270A4 (en) | METHODS FOR TREATING INFLAMMATION | |
TWI563128B (en) | Methods for treating aluminum surfaces | |
GB201302035D0 (en) | UV Apparatus | |
EP3082251A4 (en) | MOTOR DRIVE DEVICE | |
GB201322174D0 (en) | Process for treating steel components | |
ZA201506163B (en) | Methods for treating osteogenesis imperfecta | |
GB201322764D0 (en) | Treating places | |
EP2838532A4 (en) | PROCESS FOR TREATING SCLERRODERY |